Floatz logo

Cediranib

Recurrent Malignant Uterine Corpus Neoplasm

National Cancer Institute (NCI)Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Malignant Uterine Corpus Neoplasm cohort.

Asset / SponsorPhaseRating
Bms-907351
M.D. Anderson Cancer Center
Phase 2BB
(+)-VINCRISTINE
M.D. Anderson Cancer Center
Phase 2B
Tak-228
National Cancer Institute (NCI)
Phase 2B
Tazemetostat
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →